FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557135655> ?p ?o ?g. }

• W2557135655 endingPage "1483" @default.
• W2557135655 startingPage "1483" @default.
• W2557135655 abstract "Abstract Abstract 1483 Background: Activating FLT3 mutations including internal tandem duplications (FLT3-ITD) and tyrosine-kinase domain mutation (FLT3-TKD) occur in approximately one third of patients with acute myeloid leukemia (AML) and are particularly associated with a poor outcome in case of FLT3-ITD. Sunitinib is a multitargeted FLT3 inhibitor approved for the treatment of advanced/metastatic renal cancer and metastatic/unresectable malignant GIST after failure of imatinib. Sunitinib has been evaluated in refractory AML as single agent treatment resulting in transient blast count reduction and in several cases of partial response in AML with activating FLT3 mutations. Aims: To evaluate the feasibility of a standard induction and consolidation therapy in combination with orally administered sunitinib in elderly AML patients with activating FLT3 mutations. Methods: Patients aged 60 years or higher with AML with activating FLT3 mutations (FLT3-ITD, FLT3-TKD) and fit enough for intensive chemotherapy were eligible. Induction therapy included cytarabine 100 mg/m2 per continuous infusion on days 1–7 and daunorubicin 60 mg/m2 i.v. on days 1–3 (DA). A second course was allowed in responding patients, who did not achieve a complete remission (CR). In patients achieving a CR after induction therapy three consolidation cycles were intended (cytarabine 1 g/m2 i.v. bid, on days 1,3,5). A 3+3 dose escalation/de-escalation scheme was used to define the dose and scheduling of sunitinib. The first cohort of three patients received oral sunitinib continuously starting from day 1 in a dose of 25 mg/day (level 1). Dose escalation to level 2 with sunitinib 37.5 mg/day continuously or dose de-escalation to level −1 with 25 mg day 1 to 7 had been defined in the protocol. After definition of the maximally tolerated dose (MTD) an extension of the cohort at that dose was intended. Results: A total of twenty-two patients were enrolled between January 2009 and March 2011. The median age was 70 years (range 60–78), 13 were female. The type of AML was de novo in 16 pts., s-AMLin one patient and t-AML in 4 pts. Fifteen patients had a FLT3-ITD (68%) and 7 a FLT3-TKD (32%) mutation. A NPM1 mutation was present in 11 patients (50%), 15 patients exhibited a normal karyotype, 3 an intermediate-2 risk karyotype according to ELN guidelines and 2 a complex karyotype and 2 had no evaluable metaphases. In the first cohort 5 patients were treated and two experienced dose-limiting toxicity (DLT), i) prolonged hematological recovery beyond day 35 in a patient achieving a CR and ii) a hand-foot-syndrome grade III. Four of the 5 patients achieved a CR. According to the protocol the following patients received treatment at dose level −1 with sunitinib 25mg days 1 to 7. In this cohort only one DLT occurred, again prolonged hematological recovery. Thus the MTD was defined at dose level −1. Response to induction therapy in all patients was CR in 13 pts. (59%), partial remission in 1 pt. (4.5%), refractory disease in 5 pts. (23%), death in 3 pts. (13.5%). CR rate in AML with FLT3-ITD was 53% (8/15) and 71% (5/7) in those with FLT3-TKD. All 13 patients achieving CR received repetitive cycles of high-dose cytarabine consolidation therapy and 7 proceeded to single agent sunitinib maintenance therapy (median 11 months, range 1–24 months). In these patients relapse occurred in 10, one patient died due to severe colitis during consolidation therapy and two patients are in sustained CR. Two patients not achieving a CR after induction therapy underwent allogeneic stem cell transplantation form matched unrelated donors. Twelve of the 22 patients died leading to a median survival of 18.8 months and a 2 year survival of 36% (95%-CI, 19–70%). Median relapse-free survival was 11 months. Conclusion: Combination of intensive induction and consolidation therapy with oral sunitinib in AML with activating FLT3 mutations is feasible with 25 mg sunitinib given during intensive therapy on days 1 to 7 and continuously during maintenance. Disclosures: Fiedler: Novartis: Consultancy, Research Funding; Pfizer Inc.: Consultancy, Research Funding." @default.
• W2557135655 created "2016-11-30" @default.
• W2557135655 creator A5013231760 @default.
• W2557135655 creator A5018576827 @default.
• W2557135655 creator A5020375942 @default.
• W2557135655 creator A5026255080 @default.
• W2557135655 creator A5030925393 @default.
• W2557135655 creator A5033422703 @default.
• W2557135655 creator A5053949970 @default.
• W2557135655 creator A5053983155 @default.
• W2557135655 creator A5054636757 @default.
• W2557135655 creator A5066615327 @default.
• W2557135655 creator A5075459915 @default.
• W2557135655 creator A5084039929 @default.
• W2557135655 creator A5089395073 @default.
• W2557135655 date "2012-11-16" @default.
• W2557135655 modified "2023-09-30" @default.
• W2557135655 title "Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)" @default.
• W2557135655 doi "https://doi.org/10.1182/blood.v120.21.1483.1483" @default.
• W2557135655 hasPublicationYear "2012" @default.
• W2557135655 type Work @default.
• W2557135655 sameAs 2557135655 @default.
• W2557135655 citedByCount "5" @default.
• W2557135655 countsByYear W25571356552013 @default.
• W2557135655 countsByYear W25571356552014 @default.
• W2557135655 countsByYear W25571356552015 @default.
• W2557135655 countsByYear W25571356552016 @default.
• W2557135655 countsByYear W25571356552017 @default.
• W2557135655 crossrefType "journal-article" @default.
• W2557135655 hasAuthorship W2557135655A5013231760 @default.
• W2557135655 hasAuthorship W2557135655A5018576827 @default.
• W2557135655 hasAuthorship W2557135655A5020375942 @default.
• W2557135655 hasAuthorship W2557135655A5026255080 @default.
• W2557135655 hasAuthorship W2557135655A5030925393 @default.
• W2557135655 hasAuthorship W2557135655A5033422703 @default.
• W2557135655 hasAuthorship W2557135655A5053949970 @default.
• W2557135655 hasAuthorship W2557135655A5053983155 @default.
• W2557135655 hasAuthorship W2557135655A5054636757 @default.
• W2557135655 hasAuthorship W2557135655A5066615327 @default.
• W2557135655 hasAuthorship W2557135655A5075459915 @default.
• W2557135655 hasAuthorship W2557135655A5084039929 @default.
• W2557135655 hasAuthorship W2557135655A5089395073 @default.
• W2557135655 hasConcept C121608353 @default.
• W2557135655 hasConcept C126322002 @default.
• W2557135655 hasConcept C141071460 @default.
• W2557135655 hasConcept C143998085 @default.
• W2557135655 hasConcept C2776611710 @default.
• W2557135655 hasConcept C2776694085 @default.
• W2557135655 hasConcept C2778041864 @default.
• W2557135655 hasConcept C2778496288 @default.
• W2557135655 hasConcept C2778729363 @default.
• W2557135655 hasConcept C2779490328 @default.
• W2557135655 hasConcept C71924100 @default.
• W2557135655 hasConcept C90924648 @default.
• W2557135655 hasConceptScore W2557135655C121608353 @default.
• W2557135655 hasConceptScore W2557135655C126322002 @default.
• W2557135655 hasConceptScore W2557135655C141071460 @default.
• W2557135655 hasConceptScore W2557135655C143998085 @default.
• W2557135655 hasConceptScore W2557135655C2776611710 @default.
• W2557135655 hasConceptScore W2557135655C2776694085 @default.
• W2557135655 hasConceptScore W2557135655C2778041864 @default.
• W2557135655 hasConceptScore W2557135655C2778496288 @default.
• W2557135655 hasConceptScore W2557135655C2778729363 @default.
• W2557135655 hasConceptScore W2557135655C2779490328 @default.
• W2557135655 hasConceptScore W2557135655C71924100 @default.
• W2557135655 hasConceptScore W2557135655C90924648 @default.
• W2557135655 hasIssue "21" @default.
• W2557135655 hasLocation W25571356551 @default.
• W2557135655 hasOpenAccess W2557135655 @default.
• W2557135655 hasPrimaryLocation W25571356551 @default.
• W2557135655 hasRelatedWork W2016381406 @default.
• W2557135655 hasRelatedWork W2034612532 @default.
• W2557135655 hasRelatedWork W2383814905 @default.
• W2557135655 hasRelatedWork W2557135655 @default.
• W2557135655 hasRelatedWork W2997709950 @default.
• W2557135655 hasRelatedWork W3010336760 @default.
• W2557135655 hasRelatedWork W3030223433 @default.
• W2557135655 hasRelatedWork W3032889600 @default.
• W2557135655 hasRelatedWork W3133176200 @default.
• W2557135655 hasRelatedWork W3134895066 @default.
• W2557135655 hasVolume "120" @default.
• W2557135655 isParatext "false" @default.
• W2557135655 isRetracted "false" @default.
• W2557135655 magId "2557135655" @default.
• W2557135655 workType "article" @default.